Paysign (PAYS) Investor presentation summary

Strategic positioning and business overview

• Holds approximately 45.5% share of the U.S. plasma payments market, serving 561 facilities and 8.4 million cardholders as of August 2026.

• Operates a dual-engine platform: plasma donor compensation/payment and pharmaceutical patient affordability solutions.

• Proprietary Dynamic Business Rules technology delivers 97% first-fill detection accuracy, protecting manufacturer funds and patient access.

• Integrated payments and software stack, with regulatory compliance as a core differentiator.

• Fixed infrastructure enables scalable growth across both business lines.

Financial performance and growth

• FY2025 revenue reached $82.0M (+40.5% YoY), with adjusted EBITDA of $19.9M (+107.3% YoY) and gross margin of 59.4%.

• Patient affordability revenue grew 85.2% YoY in H1 2026 to $30.3M, with a 3-year CAGR of 183%.

• Plasma revenue was $45.6M in FY2025 (+4.0% YoY), with steady, recurring growth.

• No bank debt; capital-light model with expanding margins and strong operating leverage.

• 2026 guidance raised: revenue $114.0M–$117.0M (+39–43% YoY), adjusted EBITDA $35.0M–$38.0M.

Business line details and operational highlights

• Plasma: Instant donor payments, integrated software (Apherion), and data analytics drive donor retention and operational efficiency.

• Patient affordability: End-to-end copay program management, real-time claims adjudication, and proprietary fraud/abuse detection.

• Dynamic Business Rules counter PBM maximizer/accumulator tactics, saving $325M+ in manufacturer copay funds in FY2025.

• Revenue mix shifting: patient affordability now 41.3% of FY2025 revenue, up from 21.7% in 2024.

• Modular SaaS platform (Apherion) adds recurring, higher-margin revenue on top of payments.